Authors:
Beatriz Caiuby Labate Chacruna Institute for Psychedelic Plant Medicines, United States
Graduate Theological Union, United States

Search for other papers by Beatriz Caiuby Labate in
Current site
Google Scholar
PubMed
Close
https://orcid.org/0000-0002-9795-0859
,
Henrique Fernandes Antunes Chacruna Institute for Psychedelic Plant Medicines, United States
The Brazilian Center of Analysis and Planning (CEBRAP), Brazil

Search for other papers by Henrique Fernandes Antunes in
Current site
Google Scholar
PubMed
Close
https://orcid.org/0000-0002-4215-9314
,
Jamie Beachy Chacruna Institute for Psychedelic Plant Medicines, United States
Emory Center for Psychedelics and Spirituality, United States

Search for other papers by Jamie Beachy in
Current site
Google Scholar
PubMed
Close
https://orcid.org/0009-0009-9513-7862
,
Jordan Sloshower Chacruna Institute for Psychedelic Plant Medicines, United States
Department of Psychiatry, Yale University School of Medicine, United States

Search for other papers by Jordan Sloshower in
Current site
Google Scholar
PubMed
Close
https://orcid.org/0000-0001-8503-7387
, and
Clancy Cavnar Chacruna Institute for Psychedelic Plant Medicines, United States
The Interdisciplinary Group for Psychoactive Studies (NEIP), Brazil

Search for other papers by Clancy Cavnar in
Current site
Google Scholar
PubMed
Close
Open access

published online ahead of print in 2025, DOI: https://doi.org/10.1556/2054.2024.00429

In the chapter Risk of medicalization, in the second paragraph of the second column, in the following sentence:

While an extreme lack of attention to context could lead to unethical experimentation, as occurred in some instances during the first wave of scientific research into psychedelics in the 1950s and 60s (Strauss, de la Salle, Sloshower, & Williams, 2022), more subtle harms in psychedelic clinical trials can arise from methodological imperatives to have clinical trial participants wean off all other forms of treatment, use single dose paradigms to preserve blinding, and minimize psychotherapeutic support and follow up.

The citation (Strauss, de la Salle, Sloshower, & Williams, 2022), is incorrect, it should read:

While an extreme lack of attention to context could lead to unethical experimentation, as occurred in some instances during the first wave of scientific research into psychedelics in the 1950s and 60s (Hartogsohn 2017), more subtle harms in psychedelic clinical trials can arise from methodological imperatives to have clinical trial participants wean off all other forms of treatment, use single dose paradigms to preserve blinding, and minimize psychotherapeutic support and follow up.

The reference Hartogsohn (2017) is listed in References of the article.

We apologize for the mistake.

The Authors

  • Collapse
  • Expand

Editor-in-Chief:

Attila Szabo - University of Oslo

E-mail address: attilasci@gmail.com

Managing Editor:

Zsófia Földvári, Oslo University Hospital

 

Associate Editors:

  • Alexander De Foe, School of Educational Psychology and Counselling, Monash University, Australia
  • Zsolt Demetrovics - Eötvös Loránd University, Budapest, Hungary
  • Ede Frecska, founding Editor-in-Chief - University of Debrecen, Debrecen, Hungary
  • David Luke - University of Greenwich, London, UK
  • Dennis J. McKenna- Heffter Research Institute, St. Paul, USA
  • Jeremy Narby - Swiss NGO Nouvelle Planète, Lausanne, Switzerland
  • Rick Strassman - University of New Mexico School of Medicine, Albuquerque, NM, USA
  • Enzo Tagliazucchi - Latin American Brain Health Institute, Santiago, Chile, and University of Buenos Aires, Argentina
  • Michael Winkelman - Retired from Arizona State University, Tempe, USA 

Book Reviews Editor:

Michael Winkelman - Retired from Arizona State University, Tempe, USA

Editorial Board

  • Gábor Andrássy - University of Debrecen, Debrecen, Hungary
  • Paulo Barbosa - State University of Santa Cruz, Bahia, Brazil
  • Michael Bogenschutz - New York University School of Medicine, New York, NY, USA
  • Petra Bokor - University of Pécs, Pécs, Hungary
  • Jose Bouso - Autonomous University of Madrid, Madrid, Spain
  • Zoltán Brys - Multidisciplinary Soc. for the Research of Psychedelics, Budapest, Hungary
  • Susana Bustos - California Institute of Integral Studies San Francisco, USA
  • Robin Carhart-Harris - Imperial College, London, UK
  • Per Carlbring - Stockholm University, Sweden
  • Valerie Curran - University College London, London, UK
  • Alicia Danforth - Harbor-UCLA Medical Center, Los Angeles, USA
  • Alan K. Davis - The Ohio State University & Johns Hopkins University, USA
  • Rick Doblin - Boston, USA
  • Tra-ill Dowie - Ikon Institute of Australia, Australia
  • Rafael G. dos Santos - University of Sao Paulo, Sao Paulo, Brazil
  • Genis Ona Esteve - Rovira i Virgili University, Spain
  • Silvia Fernandez-Campos
  • Evgenia Fotiou - University of Crete, Greece
  • Zsófia Földvári - Oslo University Hospital, Oslo, Norway
  • Andrew Gallimore - University of Cambridge, Cambridge, UK
  • Fernanda Gebara - independent scholar, working with the Yorenka Tasorentsi Institute, Brazil
  • Neal Goldsmith - private practice, New York, NY, USA
  • Charles Grob - Harbor-UCLA Medical Center, Los Angeles, CA, USA
  • Stanislav Grof - California Institute of Integral Studies, San Francisco, CA, USA
  • Karen Grue - private practice, Copenhagen, Denmark
  • Christine Hauskeller, University of Exeter, UK
  • Jiri Horacek - Charles University, Prague, Czech Republic
  • Lajos Horváth - University of Debrecen, Debrecen, Hungary
  • Robert Jesse - Johns Hopkins University School of Medicine, Baltimore, MD, USA
  • Matthew Johnson - Johns Hopkins University School of Medicine, Baltimore, MD, USA
  • Eli Kolp - Kolp Institute New, Port Richey, FL, USA
  • Stanley Krippner - Saybrook University, Oakland, CA, USA
  • Evgeny Krupitsky - St. Petersburg State Pavlov Medical University, St. Petersburg, Russia
  • Rafael Lancelotta - Innate Path, Lakewood, CO, USA
  • Andy Letcher - University of Exeter, UK
  • Anja Loizaga-Velder - National Autonomous University of Mexico, Mexico City, Mexico
  • Luis Luna - Wasiwaska Research Center, Florianópolis, Brazil
  • Katherine MacClean - Johns Hopkins University School of Medicine, Baltimore, MD, USA
  • Deborah Mash - University of Miami School of Medicine, Miami, USA
  • Friedericke Meckel - private practice, Zurich, Switzerland
  • Ralph Metzner - California Institute of Integral Studies, San Francisco, CA, USA
  • Michael Mithoefer - private practice, Charleston, SC, USA
  • Levente Móró - University of Turku, Turku, Finland
  • David Nichols - Purdue University, West Lafayette, IN, USA
  • David Nutt - Imperial College, London, UK
  • Torsten Passie - Hannover Medical School, Hannover, Germany
  • Janis Phelps - California Institute of Integral Studies, San Francisco, CA, USA
  • József Rácz - Semmelweis University, Budapest, Hungary
  • Christian Rätsch - University of California, Los Angeles, Los Angeles, CA, USA
  • Sidarta Ribeiro - Federal University of Rio Grande do Norte, Natal, Brazil
  • William Richards - Johns Hopkins School of Medicine, Baltimore, MD, USA
  • Stephen Ross - New York University, New York, NY, USA
  • Brian Rush - University of Toronto, Toronto, Canada
  • Eduardo Schenberg - Federal University of São Paulo, São Paulo, Brazil
  • Ben Sessa - Cardiff University School of Medicine, Cardiff, UK
  • Lowan H. Stewart - Santa Fe Ketamine Clinic, NM, USA (Medical Director)
  • Rebecca Stone - Emory University, Atlanta, GA, USA
  • Csaba Szummer - Károli Gáspár University of the Reformed Church, Budapest, Hungary
  • Julien Tempone-Wiltshire - Australian College of Applied Psychology, Australia
  • Manuel Torres - Florida International University, Miami, FL, USA
  • Luís Fernando Tófoli - University of Campinas, Campinas, Brazil State
  • Malin Uthaug - Maastricht University, Maastricht, The Netherlands
  • Julian Vayne - Norwich, UK
  • Nikki Wyrd - Norwich, UK

Attila Szabo
University of Oslo

E-mail address: attilasci@gmail.com

Indexing and Abstracting Services:

  • Web of Science ESCI
  • Biological Abstracts
  • BIOSIS Previews
  • APA PsycInfo
  • DOAJ
  • Scopus
  • CABELLS Journalytics

2024  
Scopus  
CiteScore  
CiteScore rank  
SNIP  
Scimago  
SJR index 0.54
SJR Q rank Q1

2023  
Web of Science  
Journal Impact Factor 2.2
Rank by Impact Factor Q2 (Psychology, Multidisciplinary)
Journal Citation Indicator 0.89
Scopus  
CiteScore 2.5
CiteScore rank Q1 (Anthropology)
SNIP 0.553
Scimago  
SJR index 0.503
SJR Q rank Q1

Journal of Psychedelic Studies
Publication Model Gold Open Access
Submission Fee none
Article Processing Charge €990
Subscription Information Gold Open Access
Regional discounts on country of the funding agency World Bank Lower-middle-income economies: 50%
World Bank Low-income economies: 100%
Further Discounts Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100%. 
   

Journal of Psychedelic Studies
Language English
Size A4
Year of
Foundation
2016
Volumes
per Year
1
Issues
per Year

4

Founder Akadémiai Kiadó
Debreceni Egyetem
Eötvös Loránd Tudományegyetem
Károli Gáspár Református Egyetem
Founder's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
H-4032 Debrecen, Hungary Egyetem tér 1.
H-1053 Budapest, Hungary Egyetem tér 1-3.
H-1091 Budapest, Hungary Kálvin tér 9.
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 2559-9283 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Jan 2025 0 0 0
Feb 2025 0 0 0
Mar 2025 0 0 0
Apr 2025 0 6386 44
May 2025 0 5203 34
Jun 2025 0 141 19
Jul 2025 0 0 0